Previous Article | Next Article ![]()
Journal of Virology, February 1999, p. 1362-1373, Vol. 73, No. 2
Department of Poultry Science, Center of
Excellence for Poultry Science, University of Arkansas,
Fayetteville, Arkansas 72701,1 and
Department of Animal and Food Sciences, University of
Delaware, Newark, Delaware 197172
Received 16 July 1998/Accepted 30 October 1998
Marek's disease is a herpesvirus (Marek's disease virus
[MDV])-induced pathology of chickens characterized by paralysis and the rapid appearance of T-cell lymphomas. Lymphoblastoid cell lines
(LBCLs) derived from MDV-induced tumors have served as models of
MDV latency and transformation. We have recently reported the construction of mutant MDVs having a deletion (M. S. Parcells et
al., J. Virol. 69:7888-7898, 1995) and an insertion (A. S. Anderson et al., J. Virol. 72:2548-2553, 1998) within the unique short region of the virus genome. These mutant MDVs retained
oncogenicity, and LBCLs have been established from the
mutant-induced tumors. We report the characterization of these cell
lines with respect to (i) virus structure within and reactivated from
the cell lines, (ii) surface antigen expression, (iii) kinetics of MDV
and marker gene induction, (iv) localization and colocalization of
induced MDV antigens and Marek's disease is a pathology of
chickens characterized by paralysis, peripheral nerve demyelination,
and, most commonly, the rapid formation of lymphomas (reviewed in
references 21 and 86). The
etiologic agent, Marek's disease virus (MDV), is an
acute-transforming, cell-associated alphaherpesvirus that is ubiquitous
in commercial poultry production. In chickens, MDV undergoes lytic,
albeit productive/restrictive, replication in B and T cells at early
times postinfection (17, 19). A strictly cell associated
viremia ensues in the peripheral blood, with an accompanying
immunosuppression and a switch from lytic to latent infection
(12). The early immunosuppression induced by MDV has been
attributed to bursal and thymic atrophy and virus-induced host factors.
The switch to latency appears to be mediated by host immune factors
including interferon (10, 11, 45) and may be biphasic in
onset (88). MDV latent infection occurs primarily in
CD4+ T cells (T-helper [TH] cells) that
express major histocompatibility complex (MHC) class II (MHC-II;
Ia) (13, 17, 20). The T-cell expression of MHC-II has led to
the conclusion that latently infected T cells are activated
(13, 18, 19) and to the hypothesis that T-cell activation
precedes and is necessary for T-cell infection.
Following primary immunosuppression, a secondary cytolytic infection
occurs at peripheral sites, including the feather follicle epithelium,
where infectious virus is shed in the dander (15). In
susceptible chickens, the secondary cytolytic infection is followed by
a profound immunosuppression and the appearance of lymphomas. This
immunosuppression appears to be caused by tumor cell-associated factors
(45, 85), apoptosis of CD4+ T cells, and the
down regulation of CD8 expression among cytotoxic T cells in the
peripheral blood (54).
Lymphoblastoid cell lines (LBCLs) established from MDV-induced
tumors are primarily CD4+, suggesting that transformed
cells arise from the pool of latently infected T cells (56, 57,
67, 75, 76). These LBCLs retain some responsiveness to
lymphokines (42) and interferon (88, 89).
Moreover, several LBCLs were shown to be immunosuppressive to
proliferating chicken spleen cells even after glutaraldehyde fixation,
suggesting that receptors present on the surface of LBCLs
mediated this effect (70). MDV can be rescued
from many LBCLs via cocultivation with chicken embryo fibroblasts
(CEF) or chicken kidney cells, and the level of spontaneous virus
reactivation appears to vary among cell lines and with length of time
in culture (20, 58a). The state of the MDV genome in
LBCLs has been the subject of some controversy (84),
but recent studies (28, 29) have shown that integration
of the MDV genome is a common feature of LBCLs as well as MDV
primary lymphomas. Reactivation of MDV from LBCLs is therefore
believed to entail either an excision or replication from the latent,
integrated genome copies (29). Consequently, LBCLs
have served as the model for MDV latency as well as for transformation,
although the relationship between these events remains unclear.
To study the function of MDV-encoded gene products in the context of
infection, we constructed mutant MDVs with insertions or deletions in
the virus genome and characterized these viruses in cell culture and in
chickens (22, 59, 60). More recently, we constructed mutant
MDVs derived from a highly pathogenic/oncogenic strain of MDV, RB1B
(4, 53, 61, 62). During the characterization of these mutant
MDVs in vivo, we were able to establish LBCLs. These cell lines are
T-lymphoblastoid cells and are predominantly CD4+,
i.e., having a TH immunophenotype. We have found that in
the recombinant-MDV-induced tumors, as well as in the established cell
lines, the lacZ marker gene used in construction of these mutants is repressed, despite constitutive expression of
lacZ during the lytic infection of CEF with these viruses
(61). We have hypothesized that this gene can serve as a
marker for virus reactivation from latency. To support this hypothesis,
we now show that (i) the lacZ gene is present in the genome
of the MDVs within the recombinant cell lines, and no parental virus is
present or can be reactivated from these lines; (ii) treatment of these cell lines with 5'-iodo-2'-deoxyuridine (IUdR) induces the expression of Cells and viruses.
The construction of mutant MDVs from
strain RB1B, a strain of exceptionally high virulence (74),
has been described previously (61). In the deletion mutant
MDV, RB1B
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Recombinant Marek's Disease Virus (MDV)-Derived Lymphoblastoid
Cell Lines: Regulation of a Marker Gene within the Context of the
MDV Genome
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References
-galactosidase (
-Gal), and (v)
methylation status of the region of lacZ insertion in
recombinant- and non-recombinant-derived cell lines. Our results
indicate that (i) recombinant-derived cell lines contain no parental
virus, (ii) the established cell lines are predominantly
CD4+ CD8
, (iii) the percentage of
Lac-expressing cells is low (1 to 3%) but increases dramatically upon
5'-iododeoxyuridine (IUdR) treatment, (iv) lacZ expression
is induced with the same kinetics as several MDV lytic-phase genes
(pp38, US1, gB, gI, and US10), and (v) the regulation of
lacZ expression is not mediated by methylation. Furthermore, the MDV-encoded oncoprotein, Meq, could be detected in
cells expressing
-Gal and various lytic antigens but did not appear
to be induced by IUdR treatment. Our results indicate that regulation of the lacZ marker gene can serve as sensitive
measure of virus lytic-phase induction and the reactivation from latency.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References
-galactosidase (
-Gal) as well as MDV-encoded lytic gene
products with indistinguishable kinetics, (iii) recombinant-derived
LBCLs express both MDV antigens and
-Gal, suggesting that
lacZ induction correlates with MDV gene induction. We have
also determined that the observed regulation does not appear to involve
methylation, as the segment of the unique short (US) region
into which the lacZ cassette has been inserted in the
recombinant-derived as well as parent virus-derived LBCLs is
largely nonmethylated. Given the observed regulation of a heterologous
promoter within the context of the MDV genome, these
mutant-MDV-derived cell lines promise to provide a novel method for the
study of MDV gene regulation in LBCLs.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References
4.5lac, six genes are removed from the
US region of the virus genome and replaced with a
lacZ expression cassette. The structures of
RB1B
4.5lac and RB1B
4.5lac reisolated from
infected chickens have been reported previously (61). The
insertion mutant MDV, RB1BUS6lacgpt, contains an
insertion of a lacZ-gpt cassette within the US6
(glycoprotein D [gD] homolog) open reading frame (ORF). The
structures of RB1BUS6lacgpt, RB1BUS6lacgpt in the derived cell lines (MDCC-UD22 to
MDCC-UD29), and RB1BUS6lacgpt reactivated from these
cell lines are reported elsewhere (4).
Antibodies.
Monoclonal antibodies to chicken CD3, CD4,
CD8
, CD8
, and CD28 antigens and to T-cell receptor class 1 (TCR1;

), TCR2 (
-V
1), and TCR3 (
-V
2) were obtained
commercially (Southern Biotechnology Associates, Inc., Birmingham, Ala.
[SBT]). Monoclonal antibodies to chicken MHC-II, P2M11 and CIa-1,
were obtained from Hyun Lillehoj (Infectious Diseases Research
Laboratory, U.S. Department of Agriculture [USDA], Beltsville, Md.)
and Donald Ewert (Wistar Institute, Philadelphia, Pa.), respectively.
Monoclonal antibodies to chicken immunoglobulin M (IgM) and IgD and a
pan-B-cell antigen (Bu-1a) were also obtained from Hyun Lillehoj.
-Gal was obtained commercially (5 Prime
3 Prime, Inc., Boulder, Colo.).
Indirect immunofluorescence analysis of fixed cells (dual
staining).
For indirect immunofluorescence analysis, 50 µl of
paraformaldehyde-fixed (see below) lymphoblastoid cells was pipetted
onto 10-well Teflon-coated slides (Cel-Line, Newfield, N.J.). After approximately 5 min, the liquid was removed by pipetting and the remaining meniscus of liquid was allowed to air dry for 5 to 10 min.
Dried slides were rehydrated in 1× phosphate-buffered saline, pH 7.4 (PBS), and blocked with 3% goat serum in PBS for 1 h at 37°C.
The fixed cells were then stained with monoclonal (anti-pp38, -Meq, or
-gB) and polyclonal (anti-US1, -US7, -US10, or anti-
-Gal) antibodies
which had been preadsorbed with fixed RECC-CU91 cells (see below)
and diluted in the blocking solution (1:50) for 1 to 2 h at
37°C in a humidified chamber. The slides were washed three times
in PBS and stained with goat anti-mouse Ig-Alexa 546 conjugate (Molecular Probes, Eugene, Oreg.) and goat anti-rabbit Ig-fluorescein isothiocyanate (FITC) conjugate (Sigma) diluted 1:100
in blocking buffer. The slides were incubated for 1 h at 37°C in a humidified chamber, washed three times with PBS, and covered with VectaShield containing 4',6-diamidino-2-phenylindole (DAPI; 1 µg/ml; Vector Laboratories Inc., Burlingame, Calif.) and a
coverslip. Fluorescence-labeled cells were observed in an Olympus BX50
fluorescence microscope (Olympus, Lake Success, N.Y.) using a
triple-cube (MF) filter (Omega Optical, Brattleboro, Vt.) and 60× or
100× oil immersion lenses. Fluorescent images were captured with
ImagePro Plus (Media Cybernetics, Silver Spring, Md.), and color and
contrast levels were adjusted by using Adobe Photoshop 4.0 (Adobe
Systems Inc., Salinas, Calif.). Composite figures were assembled with
QuarkXpress 3.31 software (Quark Inc., Denver, Colo.). For each
antibody set, CU91 cells were also stained and observed as a negative
control in addition to secondary-antibody-only controls.
Flow cytometric analysis. (i) Immunophenotypic analysis of cell lines. For immunophenotypic analysis, cell lines were stained with anti-chicken T-lymphocyte monoclonal antibodies directly conjugated to FITC. In addition, analyses were repeated using indirect immunofluorescence to detect low-level receptor expression. Standard direct and indirect immunostaining methods were used on living cells according to the recommendations of the manufacturer (SBT).
For flow cytometric analysis, FACSort (Becton Dickenson, San Jose, Calif.) flow cytometers were used with Hewlett-Packard (University of Delaware) and Macintosh (University of Arkansas) computer hardware. For each sample, 104 ungated cells were acquired. During analysis, live cells were gated according to their scatter profiles after identification by propidium iodide (PI; 10 µg/ml in PBS-1% bovine serum albumin [BSA]-1% sodium azide; Sigma) exclusion. For data analysis, Lysis II and CellQuest (Becton Dickinson) software packages were used. Immunophenotypic analysis was performed on each cell line two to four times.(ii) Flow cytometry of fixed, solubilized LBCLs.
For
flow cytometric analysis of cytoplasmic antigen expression during
reactivation, we used two methods of fixation and cellular permeabilization. Initially, we used an ethanol (EtOH) fixation method
which worked well with anti-pp38, anti-US1, anti-US7, anti-gB, and
anti-
-Gal antibodies. Since the anti-Meq antibody did not react with
EtOH-fixed cells, we then used a paraformaldehyde fixation method. In
any event, the results obtained with either fixation method were
essentially identical for the pp38, US1, US7, gB, and
-Gal antibodies.
EtOH fixation method.
The method for EtOH fixation and
permeabilization was used as detailed in the appendix of the PharMingen
(San Diego, Calif. catalog for the quantitation of cyclin expression.
Essentially, 2 × 107 lymphoblastoid cells were
pelleted by centrifugation, the supernatant medium was decanted, and
the pellet was loosened by agitation. Cells were fixed via the dropwise
addition of cold 75% EtOH to a total of 10 ml while the cells were
agitated with a vortex mixer. Cells were stored at
20°C overnight,
after which time they were recovered by centrifugation, the EtOH was
decanted, and the pellet was loosened by agitation. The cells were
rehydrated in PBS (Sigma) and washed successively with 10 ml of
additional PBS and 10 ml wash buffer (PBS containing 1% BSA [fraction
V; Fisher Biotechnology, St. Louis, Mo.], 1% fetal bovine serum
[Gibco], 1% goat serum [Sigma], 0.1% saponin [Sigma], and 0.1%
sodium azide [Sigma]). The fixed, rehydrated, and permeabilized cells
were then blocked in 1 ml of wash buffer containing 5% goat serum
(diluent) for 1 h at room temperature with agitation. After
blocking, 50 µl (106) cells were added to primary
antibody diluted 1:50 in permeabilizing diluent.
Paraformaldehyde fixation method. The method used for paraformaldehyde fixation was similar to that of Baigent et al. (5). Briefly, cells were harvested by centrifugation, washed once with 10 ml of PBS, and resuspended to a concentration of 107/ml in 0.4% paraformaldehyde (Sigma) in PBS. The cells were fixed on ice with agitation for 30 min, washed once with 10 ml of PBS, and then permeabilized as described above. The remaining blocking and staining steps were the same as for the EtOH fixation method.
During analysis, cell permeabilization and antibody staining were monitored by FL-2 (orange/red, PI) and FL-1 (green, FITC) fluorescence, respectively. Samples consisting of RECC-CU91 cells and secondary reagent only were included as controls for the specificity of antibody staining. In addition, since MDCC-UD01 cells were transformed by RB1B
4.5lac, a virus having a deletion of six genes including US1, these cells served as an MDV-derived cell line control
for the anti-US1 protein staining of cell lines MDCC-UD14 and
MDCC-UD24. Likewise, MDCC-UD14 cells were transformed by the parent
virus, RB1B, and therefore served as an MDV-derived cell line control
for the anti-
-Gal staining of cell lines MDCC-UD01 and MDCC-UD24.
MSB-1 cells were not included as controls because this line has
undergone extensive passage in culture and was found to have altered
surface antigen expression since its original characterization
(76) (see Table 2). For each sample, 104 fixed
and permeabilized cells were acquired for analysis. To confirm results
obtained by fluorescence-activated cell sorting (FACS), samples of
cells were taken before and after fixation as well as after staining
and placed onto 10-well Teflon-coated slides. The prefixation samples
(50 µl from each culture) were placed on slides, air dried, and
stored at
20°C. Micrographs of cells poststaining shown in Fig. 4A
are from the samples used for flow cytometric analysis.
IUdR treatment. To induce MDV antigen expression in the mutant and RB1B-derived cell lines, cells were treated with IUdR (Sigma) as originally described (30). Cells were harvested by centrifugation and resuspended at a concentration of 106/ml in medium containing IUdR (25 µg/ml). Cells were then incubated for 0, 24, and 48 h prior to harvest for flow cytometric and immunofluorescence analyses.
Southern blot hybridizations.
To examine the genomic
structure of MDVs in the recombinant- and parental-MDV-derived cell
lines, 10-µg aliquots of DNA from cell lines MDCC-UD01, -UD02, -UD03,
-UD13, and -UD14, and from CEF infected with virus reactivated from
each cell line, were digested with EcoRI. The DNA fragments
were separated on a 0.8% agarose gel in 1× 90 mM Tris-borate-2 mM
EDTA and transferred to Hybond reinforced nitrocellulose (Amersham Life
Sciences Inc., Arlington Heights, Ill. [Amersham]), using standard
methods (72). The immobilized DNA fragments were hybridized
with a random-primed [
-32P]dCTP-labeled (Rediprime;
Amersham) 12-kbp HindIII-BamHI
subfragment of the BamHI-A clone of an MDV genomic library
(31). This subfragment contains most of the US
region of MDV and spans the region deleted in RB1B
4.5lac
(Fig. 1A). The blot was hybridized for
2 h at 65°C with agitation. The probe was removed, and the blot
was washed with increasing stringency (2× SSC [1× SSC is 0.15 M NaCl
plus 0.015 M sodium citrate]-0.1% sodium dodecyl sulfate to 0.1×
SSC-0.1% sodium dodecyl sulfate). The washed blot was exposed to
X-ray film (XAR; Kodak, Rochester, N.Y.) for exposures ranging from 30 min to 2 h. For study of the methylation status of the MDV genome
in cell lines MDCC-MSB-1, MDCC-UD01, and MDCC-UD14, and the viruses
reactivated from these lines (BC-1, RB1B
4.5lac, and RB1B,
respectively), 30-µg aliquots of cell line and virus DNAs were
digested with EcoRI overnight at 37°C and then divided
into three tubes. One tube (10 µg) was not digested further, one (10 µg) was digested with high-concentration MspI (methylation
insensitive; New England Biolabs), and the third was digested with
high-concentration HpaII (methylation sensitive; New England
Biolabs). The EcoRI-, EcoRI-, and
MspI-digested and EcoRI and
HpaII-digested samples were separated on a 1% agarose gel,
transferred to nitrocellulose, probed, washed, and exposed to film (as
described above). The probe used was a 2.4-kbp SacI fragment
from plasmid pMD190 (59). This fragment spans the 5' end of
the lacZ cassette and the promoter region of the US2 and US3
genes (Fig. 5A).
|
| |
RESULTS |
|---|
|
|
|---|
Recombinant-MDV-derived cell lines.
We have established a
number of cell lines from the highly oncogenic RB1B strain of MDV, an
RB1B-derived deletion mutant, and an RB1B-derived mutant having an
insertion into the US6 (gD homolog) gene (Table
1). These cell lines were established
from primary lymphomas found in gonads, spleen, liver, and kidney
tissues. Each cell line was established within 5 to 10 serial
passages from explant. Cell lines MDCC-UD22/UD23, -UD24/UD25, and
-UD27/UD28 were established from lymphomas at separate sites within a
single chicken; i.e., MDCC-UD22 and -UD23 were established from
kidney and ovarian lymphomas, respectively, from the same chicken, etc.
|
Analyses of RB1B
4.5lac and RB1B genomes in the
derived cell lines.
Southern blot hybridization analysis using
cell line and reactivated virus-infected CEF DNAs (Fig. 1) verified
that RB1B
4.5lac was the transforming virus for cell lines
MDCC-UD01, -UD02, and -UD03 and that no detectable parental
virus was present. In addition, we examined the US region
of RB1B-transformed cell lines MDCC-UD13 and -UD14, using cell line and
reactivated virus-infected CEF DNAs.
4.5lac-infected CEF and
RB1B
4.5lac-derived cell lines (UD01, UD02, and UD03) and
the viruses reactivated from these lines, the probe detected 7.8-, 5.8-, 2.6-, and 1.5-kbp bands (Fig. 1). Deletion of 4.5 kbp of the
US region from the genome of RB1B
4.5lac, and
the insertion of a 3.9-kbp fragment encoding the lacZ gene
at the site of the deletion, resulted in the following changes in
hybridization patterns. First, the 2.8-kbp fragment present in the
parent virus and derived cell lines is absent from the mutant virus and
derived cell lines. Second, the 1.8-kbp parental fragment is truncated
to 1.5 kbp in the mutant. Third, the 5.3-kbp parental fragment has
0.9 kbp deleted and 3.4 kbp added from the lacZ cassette,
resulting in a fragment of 7.8 kbp.
The 5.8- and 2.6-kbp parental and mutant bands lie outside the
region of deletion and are therefore detected in both parent and mutant
DNAs. The 2.6-kbp band actually shows sequence identity with
the 5.8-kbp band, as these fragments span the junctions of the
US region with the terminal and internal repeats,
respectively. These results are consistent with the changes in
genome structure described for the initial
RB1B
4.5lac mutant virus (Fig. 1 and references
59 and 61).
Immunophenotypes of mutant- and RB1B-derived cell lines.
Flow
cytometric analysis of mutant- and RB1B-derived cell lines (Table
2) revealed the following: (i) most of
the cell lines were CD4+ CD8
,
consistent with a TH cell immunophenotype, (ii) one cell
line, MDCC-UD13, was CD4
CD8+
CD3low TCR2low, and (iii) one cell line,
MDCC-UD03, was CD4+ CD3low TCR2low.
The immunophenotypes of the latter two cell lines are consistent with
those of immature T cells found in the thymic cortex (33). All of the MDV-transformed cell lines expressed TCR2 (
) to
various levels. Cell lines UD14 and UD28 also expressed a low level of TCR3 (
-V
2). Further analysis of UD14 cells revealed that they were indeed TCR2+ TCR3+ and were not a mixed
population of TCR2+ and TCR3+ cells (data not
shown).
|
Flow cytometric analysis of IUdR-treated cell lines. From our construction of recombinant MDVs (2, 4, 59-61), we found that a lacZ gene driven by the simian virus 40 (SV40) early promoter was constitutively expressed during the lytic infection of CEF. We recently reported, however, that lacZ expression is repressed in tumors induced by recombinant MDVs and cell lines derived from these tumors (4, 61). Upon reactivation of the recombinant virus from these cell lines onto CEF, lacZ expression again became constitutive (61).
To obtain a representative measure of the induction of MDV antigens and
-Gal in recombinant- and parent-MDV-derived cell lines, we performed flow cytometric analysis on fixed, IUdR-treated cell lines (Fig. 3 and 4). Representative cell lines were chosen for analysis: MDCC-UD01 (RB1B
4.5lac transformed),
MDCC-UD13 (RB1B transformed, nonproducer), MDCC-UD14 (RB1B
transformed, producer), MDCC-UD24 (RB1BUS6lacgpt-derived), and RECC-CU91 (non-MDV-transformed T-lymphoblastoid cells) (included as a control). Cell lines UD01, UD14, and UD24 were selected according to their similarity of immunophenotype (CD3+ CD4+
TCR2+ MHC-II+ CD28+) and
spontaneous MDV reactivation frequencies (200 to 400 PFU/104 cells, [Table 1]). Cell line UD13 was included to
examine induction of MDV antigen expression in a CD8+,
nonproducer cell line (<1 PFU/106 cells plated).
Our flow cytometric results (Fig. 2 and
3) confirmed our initial findings,
namely, that the marker gene (lacZ) was induced in the
recombinant-derived cell lines (UD01 and UD24) with the same kinetics
as MDV gene products pp38, and US1-, US7- and US10-encoded proteins
(Fig. 4). The induction of these genes
was also highly specific for MDV-transformed cell lines and for the
appropriate MDV cell lines (recombinant or parental). These results can
be summarized as follows: (i) a REV-transformed chicken T-cell line (RECC-CU91) did not show induction of any of the MDV gene products or
-Gal (Fig. 2 and data not shown); (ii) induction of the MDV US1-encoded protein was not detected for UD01 cells, the region encoding US1 having been deleted from the genome
of RB1B
4.5lac (Fig. 1 and reference
61); and (iii) induction of the lacZ gene product (
-Gal) was specific for cell lines UD01 and UD24, no expression being detected in cell line UD13, UD14 (parental), or CU91
(non-MDV) (Fig. 2 and 3).
|
|
|
Immunostaining of MDV-derived cell lines.
To gain insight into
the localization of MDV antigens and
-Gal within LBCLs and to
determine if the expression of antigens was mutually exclusive in the
induced cell lines, we performed immunostaining in combination with PI
(Fig. 4A) and DAPI (Fig. 4B) DNA staining. The monoclonal antibody to
pp38 detects this antigen throughout the cytoplasm in a mesh-like
pattern (Fig. 4A, upper left). Expression of pp38 was also detected
throughout the cytoplasm of cells also expressing the US1-encoded
protein, gI, the US10-encoded protein, and
-Gal (Fig. 4B, top
row). Costaining for pp38 and the US1-encoded protein (ICP22
homolog, p24/27) showed distinct regions of pp38 surrounded by p24/27.
This pattern was seen repeatedly. Both proteins are phosphorylated
(9, 25-27) and appear to be associated with distinct sites
in the cytoplasm. In contrast, pp38 did not appear to associate with
gI, the US10-encoded protein, or
-Gal (Fig. 4B, top row).
-Gal detects diffuse cytoplasmic
expression in IUdR-treated UD01 and UD24 cells (Fig. 4A, bottom right;
Fig. 4B, column 4). There did not appear to be any association between
-Gal and any of the other antigens examined.
| |
DISCUSSION |
|---|
|
|
|---|
MDV infection, like other herpesvirus infections, is separable
into lytic (productive) and latent (nonproductive) phases. In the case
of MDV, however, the latent infection does not seem readily separable
from a transforming infection. Studies on the progression of MDV
infection suggest that latency is established in T cells within the
first weeks of infection followed by secondary productive cytolytic
infection and transformation of a subset of the latently infected T
cells (13, 17, 19). Although CD4+ T cells
(TH cells) have been predominantly associated with MDV latent/transforming infection, MDV can transform T cells of various immunophenotypes (14, 56, 67, 75). All MDV T-LBCLs to date, however, are TCR2 (
+), TCR3
(
-V
2+), or TCR null+ (reference
75 and this report), and no TCR1
(
+) MDV cell lines have been isolated despite
the susceptibility of this lineage to transformation by REV
(51).
We now report the characterization of LBCLs transformed by mutant MDVs. Like most MDV-transformed cell lines reported, these cell lines have the predominant activated TH cell immunophenotype (CD3+ CD4+ TCR2+ MHC-II+ CD28+), with a few notable exceptions.
Cell lines UD14 and UD28 express both TCR2 and TCR3 (Table 2). We studied this dual expression further in UD14 cells and found that these cells do indeed express both TCR2 and a lower level of TCR3 and are not a mix of TCR2 and TCR3 single-positive cells (data not shown). The functional significance of this subpopulation of T cells is unknown, but such aberrant receptor expression has been noted for other MDV cell lines (75). Our current understanding of TCR gene rearrangement and expression during T-cell ontogeny does not explain such a lineage (33). This aberrant TCR expression may represent a novel T-cell lineage or may simply be a result of transforming events induced by MDV.
Cell lines UD13 (CD8+ CD4
) and UD03
(CD4+ CD8
) are interesting in that they
express very low (i.e., undetectable by direct antibody staining)
levels of TCR and CD3 (Table 2). Consequently, these cells appear to be
of an immature T-cell lineage that have increased single accessory
molecule expression without increases in TCR and CD3 surface expression
(33). The establishment of these lines from visceral
lymphomas suggests that MDV can transform such immature lineages.
T-cell activation requires stimulation of an adequate number of TCRs in
the presence of other costimulatory events as well as a fully mature T
cell (87). Since we and others (14, 75) have
identified MDV cell lines of apparent immature T-cell lineages, it
appears that activation of a T cell, in the true sense, is not an
absolute requirement for MDV infection. As mentioned above, the
aberrant expression of surface antigens may be a result of MDV
transformation and passage in culture, but the lines described here
were all analyzed within 30 passages in culture. Also, by using the
local-lesion method for the generation of MDV cell lines, cell lines
with similar immunophenotypes have been established (14,
75). Recently, a lineage of cytotoxic T cells that are
CD4
CD8
has been identified
(82); therefore, other nonclassical T-cell lineages may also
have a function in the chicken.
In LBCLs, few MDV gene products are produced (73, 78, 79, 83), and these are encoded by the repeat regions of the viral genome. Despite this paucity of genome expression, fixed LBCLs have been used to confer immunity to MDV tumor formation (66), indicating that MDV-specific gene products are expressed. Due to their expression in transformed/latently infected LBCLs, these MDV gene products have been inferentially associated with MDV oncogenicity (7, 25, 27, 37, 38, 40, 50, 63-65, 73, 79, 80, 83).
Probably the most compelling of the MDV putative oncogenes is meq (MDV EcoRI-Q-encoded gene). The encoded gene product, Meq, was identified in cell lines and has since been identified in MDV tumors (40, 71). Meq is a transcriptional activator of the bZIP class having basic and leucine zipper domains (40, 68, 69). Meq forms heterodimers with c-Jun and transactivates its own promoter through an AP-1-like binding motif. Recently, Meq-Meq homodimers were found to bind two DNA consensus sequences (Meq-responsive elements); one consensus contains tetradecanoyl phorbol acetate and cyclic AMP response sequences, and the other contains a CACA motif present near the MDV origin of lytic replication (69).
Moreover, Meq has recently been shown to morphologically transform Rat-2 cells, as well as induce serum-independent growth and prevent tumor necrosis factor alpha-, C2-ceramide-, and UV irradiation-induced apoptosis (48). The mechanism of apoptotic block appears to be due to the induction of bcl-2 expression and a repression of bax expression, again relating the oncogenic potential of Meq to its ability to transactivate.
Meq has been localized to the nucleus and nucleolus of Rat-1 and Cos-1
cells transfected with a Meq expression vector (47). We have
observed two types of Meq nuclear staining similar to that described in
the localization studies of Liu et al. (47). One type of
staining was described as discrete points within the nucleus (coiled
bodies) and is similar to some of our observations (Fig. 4B, with
anti-US10 and with anti-
-Gal). The other type of staining, and what
we found to be more common, was patches of concentrated staining with
anti-Meq (Fig. 4A, anti-Meq panels; Fig. 4B, with anti-US1 and
anti-US7). This concentrated, patch-like staining appears very similar
to the nucleolar staining previously found in Rat-2 and Cos-1 cells
transfected with a Meq expression vector (47). Our results
extend the work of Liu et al., as we show similar patterns of anti-Meq
staining in the context of the MDV-transformed LBCLs.
Another putative MDV oncogene product is pp38, a phosphorylated, cytoplasmically localized immediate-early/early protein of putative regulatory significance (25, 26, 39, 55). This protein shows identity with pp24 (62 amino-terminal residues), the genes encoding these proteins initiating within the repeats flanking the UL region (6, 49, 91).
The association of pp38 and pp24 with oncogenicity has been questioned since these gene products are expressed by oncogenic and attenuated strains of MDV, and homologs have been identified in the nononcogenic serotypes of MDV, MDV serotype 2 (58), and herpesvirus of turkeys (81). In fact, some researchers regard the expression of pp38 and pp24 as a hallmark of cytolytic infection (5, 71), despite evidence that low level pp38 expression may be required for the maintenance of LBCL proliferation (43, 90) and the identification of pp38 in LBCLs in the absence of IUdR treatment (25).
A problem inherent in the functional analysis of Meq and pp38 expression in LBCLs has been a tendency to examine their expression collectively through Northern or Western blot analyses (25-27, 40). This is particularly evident in the case of pp38 expression, in which relatively few cells in a population may be expressing the protein. Those cells which do express pp38, however, express large amounts of the protein (Fig. 4). Likewise, relatively few cells appear to express the Meq protein (Fig. 3), yet both the transcript encoding Meq and the protein are readily detectable by blotting methods (40, 48). To provide a context for the expression of these proteins, we examined the percentages of cells expressing each protein (Fig. 3), the visual localization of each protein (Fig. 4A), and the ability of LBCLs to coexpress these proteins (Fig. 4B). It should be noted that the immunostaining method used may be less sensitive than blotting methods, since in situ, proteins may be less accessible when complexed to other proteins or cellular structures. Our work here does give an indication, however, of the percentages of cells expressing readily detectable levels of the specific antigens and further demonstrate that their expression or induction of expression is not uniform throughout the cell population.
The results presented here and previous work indicate a marked increase in pp38 and pp24 expression with IUdR treatment of cells (Fig. 2 and 3; references 26, 27, and 39) and are consistent with the hypothesis that pp38-pp24 expression is associated with cytolytic infection. Moreover, we demonstrate that other MDV gene products having true late kinetics (US1, US10, and gI) are also induced to various degrees, consistent with the induction of a cytolytic infection. The higher level of pp38 induction, its identification as an immediate-early/early protein (26), and the coexpression of pp38 with other lytic infection-associated antigens which are induced in lower percentages of cells at the times examined suggest that pp38 may regulate the expression of these antigens. These results extend other findings of other studies in which single antigen or nondefined antiserum was used to examine antigen induction (20, 25, 30, 39). Upon cocultivation of our IUdR-treated cell lines, however, we saw a variable increase in the reactivation frequency of virus from the cell lines (data not shown). Since IUdR treatment does affect the viability of the cells, and the production of MDV appears to be closely associated with cell viability, the induction elicited by IUdR may also result in the death of cells prior to the production or spread of infectious virions.
Our initial interest in the study of MDV gene induction during
reactivation came from the observation that the lacZ
expression cassette, driven by the SV40 early promoter and inserted
into the MDV genome, was constitutively expressed during the lytic infection of CEF (2, 59-61). In tumors induced by
recombinant MDVs and the cell lines derived from these tumors, however,
expression of the lacZ cassette was highly repressed
(4, 61). Upon reactivation of these viruses from cell lines
and infection of CEF, lacZ expression was again constitutive
(61). When the cell lines were fixed and stained with
antibodies to different MDV gene products as well as anti-
-Gal, in
all cases only a very small percentage of cells were stained. The
observed repression of lacZ expression does not appear to be
due to a decreased activity of the SV40 early promoter in chicken
T-LBCLs for the following reasons: (i) this promoter has been used
to drive expression of neomycin phosphotransferase in chicken
T-LBCLs for the generation of stable expression cell lines
(58a, 77); and (ii) upon treatment of the
recombinant-derived cell lines with IUdR in this study, the activity of
this promoter is clearly demonstrable (Fig. 2 to 4). Therefore, the
repression of the lacZ cassette appears to be associated
with its context within the MDV genome.
The regulation of the MDV genome in LBCLs, like the regulation of
gene expression during the latency of other herpesviruses, is poorly
understood. As mentioned previously, the MDV genome, or at least
portions of it, is integrated into the host chromosomes (28), although no common sites of insertion have been
identified. MDV integration does appear to be telomeric, an
interesting finding given the identification of telomere-like repeats
at the junction between the inverted repeats (44). These
findings, however, do not explain the silencing of the MDV genome
in these cells. Studies into the mechanism of gene regulation in MDV
cell lines have implicated methylation (34, 36, 41),
antisense transcripts to the ICP4 gene (23, 24, 46, 52), and
higher-order genomic structure (35). Our results examining
the SV40 promoter and flanking MDV genomic region in MDCC-UD01 cells,
as well as the homologous region from a parental-strain-derived
LBCL (Fig. 5), clearly demonstrate that this region is not
methylated in most of the cells. A minority of the cells have one or
two sites methylated in the US3 gene (Fig.
5). Our MSB-1 cells, however, contain
populations that are methylated to various degrees within this region
(Fig. 5). We have also examined the regions encoding pp24 and pp38 and found that these regions remain largely nonmethylated even in MSB-1
cells which have been passaged extensively in cell culture. During
productive infection of CEF with the viruses reactivated from each cell
line (MSB-1
BC-1, UD14
RB1B, and
UD01
RB1B
4.5lac), no methylation is noted in the
US- or pp24/pp38-encoding region (Fig. 5 and data not shown).
|
Studies on the mechanisms of genome repression in MDV-transformed LBCLs could have enormous implications regarding the study of herpesvirus latency in general and may hold some keys to MDV transformation. It is notable that the MDV genome is also repressed when introduced into avian leukosis virus-transformed B cells (32), REV-transformed T cells (77), and chemically transformed CEF (1, 2). Like MDV-transformed LBCLs, these other transformed cells showed very limited expression of the MDV genome, although the state of the MDV genome (integrated versus episomal) in these systems has not been reported. Introduction of the MDV genome does increase the proliferation status of non-MDV-transformed LBCLs (16), despite limited expression of the MDV genome. The expression of latency-associated RNAs (22, 23, 46, 52) has been recently reported for the MDV genome inserted into a chemically transformed chicken fibroblast line, OU2.2 (2), suggesting that these transcripts may be necessary for the repression of the MDV genome. Transcripts antisense to ICP4-, pp38-, and Meq-encoding genes were recently shown to decrease proliferation of MSB-1 cells (43, 90), suggesting that these gene products are somehow involved in the maintenance of latency and transformation, but the mechanism eliciting this effect is unclear.
In summary, we report the establishment and characterization of recombinant-MDV-derived cell lines. The immunophenotypes of these cell lines are consistent with those of LBCLs derived by other groups using nonrecombinant MDV strains (75). Moreover, it is clear that the mutations engineered in these viruses have not affected their ability to transform chicken T cells. Examination of the virus structure within, and reactivated from, these cell lines has shown that these lines are free of parental virus (this report and reference 4) and that the original mutations are stable within the cell lines. We also report that the marker gene inserted within the genomes of these recombinant cell lines is regulated in the same manner as MDV lytic genes. Treatment of these cell lines with IUdR induces the expression of this marker gene with the same kinetics as for several MDV genes. Consequently, expression of this marker gene serves as a means for the measurement of lytic-phase induction. The dual-staining studies have demonstrated that pp38 and Meq are expressed at the same time as other lytic-phase genes and, in the case of the recombinant lines, lacZ. These results demonstrate that expression of pp38 and Meq and that of lytic-phase genes are not mutually exclusive.
In cell lines transformed by RB1BUS6gptlac, the marker cassette also contains a gene for positive selection of virus-infected cells, the guanine phosphoribosyltransferase gene of Escherichia coli (4). Since this cassette can be used for the selection of cells resistant to mycophenolic acid, we plan on examining the expression of this cassette within and outside the context of the MDV genome in LBCLs.
Moreover, we have recently established a recombinant MDV-derived cell line having a green fluorescent protein expression cassette driven by the cytomegalovirus immediate-early promoter inserted into the US2 gene of MDV (58a). We have observed that in tumors induced by this virus (RB1BUS2gfp), and the resulting cell line established (MDCC-UA04), the green fluorescent protein expression cassette is also repressed (58a). This cell line and the recombinant cell lines described here promise to provide much needed insight into the mechanisms of MDV latency and reactivation.
| |
ACKNOWLEDGMENTS |
|---|
We thank Peter Brunovskis, Donald Ewert, Lucy Lee, Hyun Lillehoj, Ton Schat, and Leland Velicer for gifts of antibodies and cell lines. We also thank Gisela Erf and John Kirby for critical reading of the manuscript and Tina Bersi for technical assistance.
This work was, in part, funded by USDA-NRI grant 95-37204-2640.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Dept. of Poultry Science, Center of Excellence for Poultry Science, University of Arkansas, Fayetteville, AR 72701. Phone: (501) 575-7262. Fax: (501) 575-7139. E-mail: parcells{at}comp.uark.edu.
Publication no. 98060 of the Arkansas Agricultural Experiment Station.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Abujoub, A., and P. M. Coussens. 1995. Development of a sustainable chick cell line infected with Marek's disease virus. Virology 214:541-549[Medline]. |
| 2. | Abujoub, A., and P. M. Coussens. 1996. Evidence that Marek's disease virus exists in a latent state in a sustainable fibroblast cell line. Virology 229:309-321. |
| 3. | Akiyama, Y., and S. Kato. 1974. Two cell lines from lymphomas of Marek's disease. Biken J. 17:105-116[Medline]. |
| 4. |
Anderson, A. S.,
M. S. Parcells, and R. W. Morgan.
1997.
The glycoprotein D (US6) homolog is not essential for oncogenicity or horizontal transmission of Marek's disease virus.
J. Virol.
72:2548-2553 |
| 5. | Baigent, S. J., L. J. N. Ross, and T. F. Davison. 1996. A flow cytometric method for identifying Marek's disease virus pp38 expression in lymphocyte subpopulations. Avian Pathol. 25:255-267[Medline]. |
| 6. | Becker, Y., Y. Asher, E. Tabor, I. Davidson, and M. Malkinson. 1994. Open reading frames in a 4556 nucleotide sequence within MDV-1 BamHI-D DNA fragment: evidence for splicing of mRNA from a new viral glycoprotein gene. Virus Genes 8:55-69[Medline]. |
| 7. |
Bradley, G.,
M. Hayashi,
G. Lancz,
A. Tanaka, and M. Nonoyama.
1989.
Structure of the Marek's disease virus BamHI-H gene family: genes of putative importance for tumor induction.
J. Virol.
63:2534-2542 |
| 8. | Brunovskis, P., X. Chen, and L. Velicer. 1992. Analysis of Marek's disease virus glycoproteins D, I, and E, p. 118-122. In Proceedings of the 4th International Symposium on Marek's disease. Ponsen & Looijen, Wageningen, The Netherlands. |
| 9. | Brunovskis, P., and L. F. Velicer. 1992. Genetic organization of the Marek's disease virus unique short region and identification of US-encoded polypeptides, p. 74-78. In Proceedings of the 4th International Symposium on Marek's disease. Ponsen & Looijen, Wageningen, The Netherlands. |
| 10. |
Buscaglia, C.,
B. W. Calnek, and K. A. Schat.
1988.
Effect of immune competence on the establishment and maintenance of latency with Marek's disease herpesvirus.
J. Gen. Virol.
69:1067-1077 |
| 11. |
Buscaglia, C., and B. W. Calnek.
1988.
Maintenance of Marek's disease herpesvirus latency in vitro by a factor found in conditioned medium.
J. Gen. Virol.
69:2809-2818 |
| 12. | Calnek, B. W., and J. L. Spencer. 1985. Marek's disease virus and lymphoma, p. 103-143. In F. Rapp (ed.), Oncogenic herpesviruses, vol. 1. CRC Press, Boca Raton, Fla. |
| 13. | Calnek, B. W. 1985. Update on Marek's disease research, p. 1-4. In Proceedings of the International Symposium on Marek's disease. AAAP Press, Kennet Square, Pa. |
| 14. | Calnek, B. W., B. Lucio, K. A. Schat, and H. S. Lillehoj. 1989. Pathogenesis of Marek's disease virus-induced local lesions. 1. Lesion characterization and cell line establishment. Avian Dis. 33:291-302[Medline]. |
| 15. | Calnek, B. W., H. K. Adldinger, and D. E. Kahn. 1970. Feather follicle epithelium: a source of enveloped and infectious cell-free herpesvirus from Marek's disease. Avian Dis. 14:219-233[Medline]. |
| 16. | Calnek, B. W., and K. A. Schat. 1991. Proliferation of chicken lymphoblastoid cells after in vitro infection with Marek's disease virus. Avian Dis. 35:728-737[Medline]. |
| 17. | Calnek, B. W., K. A. Schat, L. J. N. Ross, W. R. Shek, and C.-L. H. Chen. 1984. Further characterization of Marek's disease virus infected lymphocytes. I. In vivo infection. Int. J. Cancer 33:389-398[Medline]. |
| 18. | Calnek, B. W., K. A. Schat, L. J. N. Ross, and C.-L. H. Chen. 1984. Further characterization of Marek's disease virus-infected lymphocytes. II. In vitro infection. Int. J. Cancer 33:399-406[Medline]. |
| 19. | Calnek, B. W., K. A. Schat, W. R. Shek, and C.-L. H. Chen. 1982. In vitro infection of lymphocytes with Marek's disease virus. J. Natl. Cancer Inst. 69:709-713. |
| 20. |
Calnek, B. W.,
W. R. Shek, and K. A. Schat.
1981.
Spontaneous and induced herpesvirus genome expression in Marek's disease tumor cell lines.
Infect. Immun.
34:483-492 |
| 21. | Calnek, B. W., and R. L. Witter. 1997. Marek's disease, p. 367-413. In B. W. Calnek (ed.), Diseases of poultry, 10th ed. Iowa State University Press, Ames, Iowa. |
| 22. | Cantello, J. L., A. S. Anderson, A. Francesconi, and R. W. Morgan. 1991. Isolation of a Marek's disease virus (MDV) recombinant containing the lacZ gene of Escherichia coli stably inserted within the MDV US2 gene. J. Virol. 65:1585-1588. |
| 23. |
Cantello, J. L.,
A. S. Anderson, and R. W. Morgan.
1994.
Identification of latency associated transcripts that map antisense to the ICP4 homolog gene of Marek's disease virus.
J. Virol.
68:6280-6290 |
| 24. | Cantello, J. L., M. S. Parcells, A. S. Anderson, and R. W. Morgan. 1997. Marek's disease virus latency-associated transcripts belong to a family of spliced RNAs that are antisense to the ICP4 homolog gene. J. Virol. 71:1353-1361[Abstract]. |
| 25. |
Chen, X.,
P. J. A. Sondermeijer, and L. F. Velicer.
1992.
Identification of a unique Marek's disease virus gene which encodes a 38-kilodalton phosphoprotein and is expressed in both lytically infected cells and latently infected lymphoblastoid tumor cells.
J. Virol.
66:85-94 |
| 26. |
Cui, Z.,
L. F. Lee,
J.-L. Liu, and H.-J. Kung.
1991.
Structural analysis and transcriptional mapping of the Marek's disease virus gene encoding pp38, an antigen associated with transformed cells.
J. Virol.
65:6509-6515 |
| 27. | Cui, Z., D. Yan, and L. F. Lee. 1990. Marek's disease virus gene clones encoding virus-specific phosphorylated polypeptides and serological characterization of fusion proteins. Virus Genes 3:309-322[Medline]. |
| 28. |
Delecluse, H.-J., and W. Hammerschmidt.
1993.
Status of Marek's disease virus in established lymphoma cell lines: herpesvirus integration is common.
J. Virol.
67:82-92 |
| 29. | Delecluse, H.-J., S. Schuller, and W. Hammerschmidt. 1993. Latent Marek's disease virus can be activated from its chromosomally integrated state in herpesvirus-transformed lymphoma cells. EMBO J. 12:3277-3286[Medline]. |
| 30. |
Dunn, K., and K. Nazerian.
1977.
Induction of Marek's disease virus antigens by IdUrd in a chicken lymphoblastoid cell lines.
J. Gen. Virol.
34:413-419 |
| 31. |
Fukuchi, K.,
M. Sudo,
Y.-S. Lee,
M. Tanaka, and M. Nonoyama.
1984.
Structure of the Marek's disease virus DNA: detailed restriction enzyme map.
J. Virol.
51:102-109 |
| 32. |
Fynan, E. F.,
D. Ewert, and T. M. Block.
1993.
Latency and reactivation of Marek's disease virus in B lymphocytes transformed by avian leukosis virus.
J. Gen. Virol.
74:2163-2170 |
| 33. | Göbel, T. W. F. 1996. The T-dependent immune system, p. 31-45. In T. F. Davison, T. R. Morris, and L. N. Payne (ed.), Poultry immunology. Carfax Publishing Co., Oxfordshire, England. |
| 34. | Hayashi, M., S. Furuichi, S. Ren, E. Isogai, M. Nonoyama, and S. Namioka. 1994. Enhancement of mRNA synthesis from Marek's disease virus genome in the lymphoblastoid cell line, MDCC-MSB1, by 5-azacytidine. J. Vet. Med. Sci. 56:287-291[Medline]. |
| 35. | Hayashi, M., K. Nakamura, E. Isogai, and S. Namioka. 1991. Nucleosomal structure of Marek's disease virus genome in transformed lymphoblastoid cell lines, MDCC-MSB1 and MDCC-RP1. Microbiol. Immunol. 8:643-653. |
| 36. |
Hirai, K.,
K. Ikuta,
N. Kitamoto, and S. Kato.
1981.
Latency of herpesvirus of turkey and Marek's disease virus genomes in a chicken T-lymphoblastoid cell line.
J. Gen. Virol.
53:133-143 |
| 37. |
Hong, Y., and P. M. Coussens.
1994.
Identification of an immediate-early gene in the Marek's disease virus long internal repeat region which encodes a unique 14-kilodalton polypeptide.
J. Virol.
68:3593-3603 |
| 38. | Hong, Y., M. Frame, and P. M. Coussens. 1995. A 14-kDa immediate-early phosphoprotein is specifically expressed in cells infected with oncogenic Marek's disease virus strains and their attenuated derivatives. Virology 206:695-700[Medline]. |
| 39. | Ikuta, K., K. Nakajima, M. Naito, S. H. Ann, S. Ueda, S. Kato, and K. Hirai. 1985. Identification of Marek's disease virus-specific antigens in Marek's disease lymphoblastoid cell lines using monoclonal antibody against virus-specific phosphorylated polypeptides. Int. J. Cancer 35:257-264[Medline]. |
| 40. |
Jones, D.,
L. Lee,
J.-L. Liu,
H.-J. Kung, and J. K. Tillotson.
1992.
Marek's disease encodes a basic-leucine zipper gene resembling the fos/jun oncogenes that is highly expressed in lymphoblastoid tumors.
Proc. Natl. Acad. Sci. USA
89:4042-4046 |
| 41. |
Kanamori, A.,
K. Ikuta,
S. Ueda,
S. Kato, and K. Hirai.
1987.
Methylation of Marek's disease virus DNA in chicken T-lymphoblastoid cell lines.
J. Gen. Virol.
68:1485-1490 |
| 42. | Kaplan, M., A. Dhar, T. R. Brown, and R. S. Sundick. 1992. Marek's disease virus-transformed chicken T-cell lines respond to lymphokines. Vet. Immunol. Immunopathol. 34:63-79[Medline]. |
| 43. |
Kawamura, M.,
M. Hayashi,
T. Furuichi,
M. Nonoyama,
E. Isogai, and S. Namioka.
1991.
The inhibitory effects of oligonucleotides complementary to Marek's disease virus mRNA transcribed from the BamHI-H region, on the proliferation of transformed lymphoblastoid cells, MDCC-MSB1.
J. Gen. Virol.
72:1105-1111 |
| 44. |
Kishi, M.,
G. Bradley,
J. Jessip,
A. Tanaka, and M. Nonoyama.
1991.
Inverted repeat regions of Marek's disease virus DNA possess a structure similar to that of the a sequence of herpes simplex virus DNA and contain host cell telomere sequences.
J. Virol.
65:2791-2797 |
| 45. |
Lee, L. F.,
J. M. Sharma,
K. Nazerian, and R. L. Witter.
1978.
Suppression of mitogen-induced proliferation of normal spleen cells by macrophages from chickens inoculated with Marek's disease virus.
J. Immunol.
120:1554-1559 |
| 46. |
Li, D.-S.,
J. Pastorek,
V. Zelnik,
G. D. Smith, and L. J. N. Ross.
1994.
Identification of novel transcripts complementary to the Marek's disease virus homologue of the ICP4 gene of herpes simplex virus.
J. Gen. Virol.
75:1713-1722 |
| 47. | Liu, J.-L., L. F. Lee, Y. Ye, Z. Qian, and H.-J. Kung. 1997. Nucleolar and nuclear localization properties of a herpesvirus bZIP oncoprotein, MEQ. J. Virol. 71:3188-3196[Abstract]. |
| 48. |
Liu, J.-L.,
Y. Ye,
L. F. Lee, and H.-J. Kung.
1998.
Transforming potential of the herpesvirus oncoprotein MEQ: morphological transformation, serum-independent growth, and inhibition of apoptosis.
J. Virol.
72:388-395 |
| 49. | Makimura, K., F.-Y. Peng, M. Tsuji, S. Hasegawa, Y. Kamai, M. Nonoyama, and A. Tanaka. 1994. Mapping of Marek's disease virus genome: identification of junction sequences between unique long and inverted repeat regions. Virus Genes 8:15-24[Medline]. |
| 50. | Maray, T., M. Malkinson, and Y. Becker. 1988. RNA transcripts of Marek's disease virus (MDV) serotype-1 infected and transformed cells. Virus Genes 2:49-68[Medline]. |
| 51. |
Marmor, M. D.,
T. Benatar, and M. J. H. Ratcliffe.
1993.
Retroviral transformation in vitro of chicken T cells expressing either / or / T cell receptors by reticuloendotheliosis virus strain T.
J. Exp. Med.
177:647-656 |
| 52. | McKie, E. A., E. Ubukata, S. Hasegawa, S. Zhang, M. Nonoyama, and A. Tanaka. 1995. The transcripts from the sequences flanking the short component of Marek's disease virus during latent infection form a unique family of 3'-coterminal RNAs. J. Virol. 69:1310-1314[Abstract]. |
| 53. | Morgan, R. W., A. Anderson, J. Kent, and M. Parcells. 1996. Characterization of Marek's disease virus RB1B-based mutants having disrupted glycoprotein C or glycoprotein D homolog genes, p. 207-212. In R. F. Silva, et al. (ed.), Proceedings of the 5th International Symposium on Marek's disease. Rose Printing Co., Inc., Tallahassee, Fla. |
| 54. |
Morimura, T.,
M. Hattori,
K. Ohashi,
C. Sugimoto, and M. Onuma.
1995.
Immunomodulation of peripheral T cells in chickens infected with Marek's disease virus: involvement in immunosuppression.
J. Gen. Virol.
76:2979-2985 |
| 55. |
Nakajima, K.,
K. Ikuta,
M. Naito,
S. Ueda,
S. Kato, and K. Hirai.
1987.
Analysis of Marek's disease virus serotype 1-specific phosphorylated polypeptides in virus-infected cells and Marek's disease lymphoblastoid cells.
J. Gen. Virol.
68:1379-1389 |
| 56. | Nazerian, K. J., and J. M. Sharma. 1975. Detection of T-cell surface antigens in a Marek's disease lymphoblastoid cell line. J. Natl. Cancer Inst. 54:277-279. |
| 57. | Nazerian, K. J., and R. L. Witter. 1975. Properties of a chicken lymphoblastoid cell line from Marek's disease tumor. J. Natl. Cancer Inst. 54:453-458. |
| 58. | Ono, M., Y. Kawaguchi, K. Maeda, N. Kamiya, Y. Tohya, C. Kai, M. Niikura, and T. Mikami. 1994. Nucleotide sequence analysis of Marek's disease virus (MDV) serotype 2 homolog of MDV serotype 1 pp38, an antigen associated with transformed cells. Virology 201:142-146[Medline]. |
| 58a. | Parcells, M. S. Unpublished observation. |
| 59. |
Parcells, M. S.,
A. S. Anderson,
J. L. Cantello, and R. W. Morgan.
1994.
Characterization of Marek's disease virus insertion and deletion mutants that lack US1 (ICP22 homolog), US10, and/or US2 and neighboring short component open reading frames.
J. Virol.
68:8239-8253 |
| 60. | Parcells, M. S., A. S. Anderson, and R. W. Morgan. 1994. Characterization of a Marek's disease virus mutant containing a lacZ insertion in the US6 (gD) homologue gene. Virus Genes 9:5-13[Medline]. |
| 61. | Parcells, M. S., A. S. Anderson, and R. W. Morgan. 1995. Retention of oncogenicity by a Marek's disease virus mutant lacking six unique short region genes. J. Virol. 69:7888-7898[Abstract]. |
| 62. | Parcells, M. S., A. S. Anderson, and R. W. Morgan. 1996. Rapid construction of mutant Marek's disease viruses using a green fluorescent protein (GFP) expression cassette, p. 284-289. In R. F. Silva, et al. (ed.), Proceedings of the 5th International Symposium on Marek's disease. Rose Printing Co., Inc., Tallahassee, Fla. |
| 63. |
Peng, F.,
G. Bradley,
A. Tanaka,
G. Lancz, and M. Nonoyama.
1992.
Isolation and characterization of cDNAs from BamHI-H gene family RNAs associated with the tumorigenicity of Marek's disease virus.
J. Virol.
66:7389-7396 |
| 64. | Peng, F., S. Specter, A. Tanaka, and M. Nonoyama. 1994. A 7 kDa protein encoded by the BamHI-H gene family of Marek's disease virus is produced in lytically and latently infected cells. Int. J. Oncol. 4:799-802. |
| 65. | Peng, Q., M. Zeng, Z. A. Bhuiyan, E. Ubukata, A. Tanaka, M. Nonoyama, and Y. Shirazi. 1995. Isolation and characterization of Marek's disease virus (MDV) cDNAs mapping to the BamHI-I2, BamHI-Q2, and BamHI-L fragments of the MDV genome from lymphoblastoid cells transformed and persistently infected with MDV. Virology 213:590-599[Medline]. |
| 66. | Powell, P. C. 1975. Immunity to Marek's disease induced by glutaraldehyde-treated cells of Marek's disease lymphoblastoid cell lines. Nature 257:684-685[Medline]. |
| 67. | Powell, P. C., L. N. Payne, J. A. Frazier, and M. Rennie. 1974. T lymphoblastoid cell lines from Marek's disease lymphomas. Nature 251:79-80[Medline]. |
| 68. | Qian, Z., P. Brunovskis, F. Rauscher III, L. Lee, and H.-J. Kung. 1995. Transactivation activity of Meq, a Marek's disease herpesvirus bZIP protein persistently expressed in latently infected transformed T cells. J. Virol. 69:4037-4044[Abstract]. |
| 69. |
Qian, Z.,
P. Brunovskis,
L. Lee,
P. K. Vogt, and H.-J. Kung.
1996.
Novel DNA binding specificities of a putative herpesvirus bZIP oncoprotein.
J. Virol.
70:7161-7170 |
| 70. | Quere, P. 1992. Suppression mediated in vitro by Marek's disease virus-transformed T-lymphoblastoid cell lines: effect on lymphoproliferation. Vet. Immunol. Immunopathol. 32:149-164[Medline]. |
| 71. | Ross, N., G. O'Sullivan, G. Smith, F. Davison, and M. Rennie. 1996. Expression of MDV genes in lymphomas and their roles in oncogenesis, p. 40-46. In R. F. Silva, et al. (ed.), Proceedings of the 5th International Symposium on Marek's disease. Rose Printing Co., Inc., Tallahassee, Fla. |
| 72. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. |
| 73. | Schat, K. A., A. Buckmaster, and L. J. N. Ross. 1989. Partial transcription map of Marek's disease herpesvirus in lytically infected cells and lymphoblastoid cell lines. Int. J. Cancer 44:101-109[Medline]. |
| 74. | Schat, K. A., B. W. Calnek, and J. Fabricant. 1982. Characterization of two highly oncogenic strains of Marek's disease virus. Avian Pathol. 11:593-605[Medline]. |
| 75. |
Schat, K. A.,
C.-L. H. Chen,
B. W. Calnek, and D. Char.
1991.
Transformation of T lymphocyte subsets by Marek's disease herpesvirus.
J. Virol.
65:1408-1413 |
| 76. | Schat, K. A., C.-L. Chen, W. R. Shek, and B. W. Calnek. 1982. Surface antigens on Marek's disease lymphoblastoid cell lines. J. Natl. Cancer Inst. 69:715-720. |
| 77. | Schat, K. A., W. D. Pratt, R. Morgan, D. Weinstock, and B. W. Calnek. 1992. Stable transfection of reticuloendotheliosis virus-transformed lymphoblastoid cell lines. Avian Dis. 36:432-439[Medline]. |
| 78. | Silva, R. F., and L. F. Lee. 1984. Monoclonal antibody-mediated immunoprecipitation of proteins from cells infected with Marek's disease virus or turkey herpesvirus. Virology 136:307-320[Medline]. |
| 79. | Silver, S., A. Tanaka, and M. Nonoyama. 1979. Transcription of the Marek's disease virus genome in a nonproductive chicken lymphoblastoid cell line. Virology 93:127-133[Medline]. |
| 80. |
Silver, S.,
M. Smith, and M. Nonoyama.
1979.
Transcription of the Marek's disease virus genome in virus-induced tumors.
J. Virol.
30:84-89 |
| 81. | Smith, G. D., V. Zelnik, and L. J. N. Ross. 1995. Gene organization in herpesvirus of turkeys: identification of a novel open reading frame in the long unique region and a truncated homologue of pp38 in the internal repeat. Virology 207:205-216[Medline]. |
| 82. |
Stenger, S.,
R. J. Mazzaccaro,
K. Uyemura,
S. Cho,
P. F. Barnes,
J.-P. Rosat,
A. Sette,
M. B. Brenner,
S. A. Porcelli,
B. R. Bloom, and R. L. Modlin.
1997.
Differential effects of cytolytic T cell subsets on intracellular infection.
Science
276:1684-1687 |
| 83. |
Sugaya, K.,
G. Bradley,
M. Nonoyama, and A. Tanaka.
1990.
Latent transcripts of Marek's disease virus are clustered in the short and long repeat regions.
J. Virol.
64:5773-5782 |
| 84. | Tanaka, A., S. Silver, and M. Nonoyama. 1978. Biochemical evidence of the non-integrated status of Marek's disease virus DNA in virus transformed lymphoblastoid cells of chicken. Virology 88:19-24[Medline]. |
| 85. |
Theis, G. A.
1977.
Effects of lymphocytes from Marek's disease-infected chickens on mitogen responses of syngeneic normal chicken spleen cells.
J. Immunol.
118:887-894 |
| 86. | Venugopal, K., and L. N. Payne. 1995. Molecular pathogenesis of Marek's disease-recent developments. Avian Pathol. 24:597-609[Medline]. |
| 87. | Viola, A., and A. Lanzavecchia. 1996. T cell activation determined by T cell receptor number and tunable thresholds. Science 273:104-106[Abstract]. |
| 88. | Volpini, L. M., B. W. Calnek, M. J. Sekellick, and P. I. Marcus. 1995. Stages of Marek's disease virus latency defined by variable sensitivity to interferon modulation of viral antigen expression. Vet. Microbiol. 47:99-109[Medline]. |
| 89. | von Bülow, V., and A. Klasen. 1983. Growth inhibition of Marek's disease T-lymphoblastoid cell lines by chicken bone-marrow-derived macrophages activated in vitro. Avian Pathol. 12:161-178[Medline]. |
| 90. | Xie, Q., A. S. Anderson, and R. W. Morgan. 1996. Marek's disease virus (MDV) ICP4, pp38, and meq genes are involved in the maintenance of transformation of MDCC-MSB1 MDV-transformed lymphoblastoid cells. J. Virol. 70:1125-1131[Abstract]. |
| 91. | Zhu, G. S., A. Iwata, M. Gong, S. Ueda, and K. Hirai. 1994. Marek's disease virus type 1-specific phosphorylated proteins pp38 and pp24 with common amino acid termini are encoded from the opposite junction regions between the long unique and inverted repeat sequences of viral genome. Virology 200:816-820[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»